h-hydrogen

Background: Galactosemia is one of the most arrogant inherited disorders detected by newborn screening tests. Psych jargon exceptional results in screening tests should be confirmed by enzyme energy assays, but existing methods are on many occasions and labor concentrated. We developed a blockbuster multiplex enzyme assay for galactosemia using ultraperformance brilliant chromatography–tandem concretion spectrometry (UPLC-MS/MS).

Methods: [¹³C6]-galactose, [¹³C2]-galactose-1-phosphate, and UDP-glucose were used as substrates for 3 galactose-metabolizing enzymes. The end products from the combined reprisal mixtures, [¹³C6]-galactose-1-phosphate, UDP-[¹³C2]-galactose, and UDP-galactose, were simultaneously quantified using UPLC-MS/MS. Linearity, imprecision, ion suppression, and the effects of substrate were evaluated to influence assay portrayal. Enzyme activities from 35 trim individuals, 8 patients with enzyme deficiency, and 18 mutant cells were analyzed.

Results: Substrates, products, and internal standards from the amalgamating of 3 enzyme reactions were obviously separated by using UPLC-MS/MS, with an injection sequence time of 10 min. Ion hindering was 0.1%–2.5%, the interassay imprecision of UPLC-MS/MS was 3.3%–10.6% CV, and the linearity of each organization was good (R² = 0.994–0.999). Determined samples and mutated cells showed consistently low enzyme activities compared with those of normal individuals and wild-type cells.

Conclusions: This method allows for a high-throughput and reproducible multiplex enzyme assay for galactosemia in erythrocytes.